{"name":"Sage category","title":"","children":[{"id":"ADC","name":"ADC","presenterLast":"ADC","children":[{"id":"639","name":"639","title":"The first ACT: an efficient data tracking and sharing tool for ADC and linker-payload development","presenterFirst":"Frank","presenterLast":"Loganzo","presenterInstitution":"Pfizer Oncology","presenterCity":"Pearl River","presenterCountry":"United States","keywords":"Databases;NA;NA;NA","category":"BIOINFORMATICS AND SYSTEMS BIOLOGY","sage":"ADC","moa":"NA"},{"id":"790","name":"790","title":"Glycoprotein NMB (gpNMB) overexpression is prevalent in human cancers: pancreatic cancer, non-small cell lung cancer, head and neck cancer, and osteosarcoma","presenterFirst":"Rebecca","presenterLast":"Bagley","presenterInstitution":"Celldex Therapeutics, Inc.","presenterCity":"Needham","presenterCountry":"United States","keywords":"Biomarker;Antibody drug conjugate;Antibody drug conjugate;Glembatumumab vedotin","category":"CLINICAL RESEARCH","sage":"ADC","moa":"NA"},{"id":"1838","name":"1838","title":"AGS62P1, a novel site-specific antibody drug conjugate targeting FLT3 exhibits potent anti-tumor activity regardless of FLT3 kinase activation status","presenterFirst":"Nandini","presenterLast":"Rudra-Ganguly","presenterInstitution":"Agensys Inc., an Affiliate of Astellas Pharma Inc.","presenterCity":"Santa Monica","presenterCountry":"United States","keywords":"Antibody;Kinases;Kinases;Therapeutics","category":"IMMUNOLOGY","sage":"ADC","moa":"NA"},{"id":"2301","name":"2301","title":"deBouganin conjugated to trastuzumab overcomes multiple mechanisms of T-DM1 drug resistance","presenterFirst":"Rachelle","presenterLast":"Dillon","presenterInstitution":"Viventia Bio Inc","presenterCity":"Winnipeg","presenterCountry":"Canada","keywords":"Immunotoxin;Antibody engineering;Antibody engineering;HER-2","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"2302","name":"2302","title":"VB7-756: a Her2-specific diabody armed with deBouganin, a plant toxin with a distinct MOA","presenterFirst":"Shilpa","presenterLast":"Chooniedass","presenterInstitution":"Viventia Bio Inc","presenterCity":"Winnipeg","presenterCountry":"Canada","keywords":"Antibody engineering;Immunotoxin;Immunotoxin;HER-2","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"2557","name":"2557","title":"Antibody drug conjugates (anti-CD79b-vc-MMAE, Polatuzumab Vedotin) exhibit enhanced cell death targeted to CD79b+ Burkitt lymphoma (BL) and primary mediastinal large B-cell lymphoma (PMBL)","presenterFirst":"Aradhana","presenterLast":"Tiwari","presenterInstitution":"New York Medical College","presenterCity":"Elsmford","presenterCountry":"United States","keywords":"B cells;Antibody engineering;Antibody engineering;Non-Hodgkin's lymphoma","category":"IMMUNOLOGY","sage":"ADC","moa":"NA"},{"id":"3381","name":"3381","title":"Assays for the selection and functional characterization of antibody-drug conjugates at the National Research Council of Canada","presenterFirst":"Maria","presenterLast":"Jaramillo","presenterInstitution":"National Research Council of Canada","presenterCity":"Montr\u00e9al","presenterCountry":"Canada","keywords":"Antibody;Therapeutics;Therapeutics;Screening","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"3796","name":"3796","title":"Development of anti-5T4 antibody-drug conjugates, ZV05-ADCs for targeted cancer therapy in different type of cancers","presenterFirst":"Hong","presenterLast":"Zhang","presenterInstitution":"Concortis Biosystem","presenterCity":"San Diego","presenterCountry":"United States","keywords":"Antibody;Antibody drug conjugate;Antibody drug conjugate;NA","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"3989","name":"3989","title":"Killing cancer one cell at a time: Development and characterization of a novel antibody drug conjugate","presenterFirst":"Michael","presenterLast":"Xiao","presenterInstitution":"Brigham Young University","presenterCity":"Pleasant Grove","presenterCountry":"United States","keywords":"Antibody;Thymidine kinase;Thymidine kinase;Targeted therapy","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"4406","name":"4406","title":"CD269 - A promising target for amanitin based ADCs","presenterFirst":"Michael","presenterLast":"Kulke","presenterInstitution":"Heidelberg Pharma GmbH","presenterCity":"Ladenburg","presenterCountry":"Germany","keywords":"Multiple myeloma;Amanitin;Amanitin;ADC","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"5505","name":"5505","title":"A novel high energy alpha-pharmaceutical:<i> In vitro</i> and <i>in vivo </i>potency of a mesothelin-targeted thorium-227 conjugate (TTC) in a model of bone disease","presenterFirst":"Urs","presenterLast":"Hagemann","presenterInstitution":"Bayer AS","presenterCity":"Oslo","presenterCountry":"Norway","keywords":"Antibody;Bone metastasis;Bone metastasis;DNA double-strand break","category":"IMMUNOLOGY","sage":"ADC","moa":"NA"},{"id":"5581","name":"5581","title":"Optimization of lead antibody selection for XMT-1522, a novel, highly potent HER2-targeted antibody-drug conjugate (ADC)","presenterFirst":"Natasha","presenterLast":"Bodyak","presenterInstitution":"Mersana Therapeutics","presenterCity":"Cambridge","presenterCountry":"United States","keywords":"Antibody;ADCC;ADCC;Herceptin","category":"IMMUNOLOGY","sage":"ADC","moa":"NA"},{"id":"410","name":"410","title":"Preclinical evaluation of targeting Notch-3 in breast cancer","presenterFirst":"Sara","presenterLast":"Hurvitz","presenterInstitution":"UCLA","presenterCity":"Santa Monica","presenterCountry":"United States","keywords":"Antibody;Novel anticancer agents;Novel anticancer agents;Breast cancer","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"440","name":"440","title":"Creating a superior, site-specific anti-HER2 antibody-drug conjugate (NG-HER2 ADC) for treatment of solid tumors","presenterFirst":"Bitha","presenterLast":"Narayanan","presenterInstitution":"Pfizer","presenterCity":"Pearl River","presenterCountry":"United States","keywords":"Antibody;Breast cancer;Breast cancer;Bystander effect","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"912","name":"912","title":"Characterization of a novel maytansinoid-antibody-drug conjugate targeting LAMP1 expressed at the surface of tumor cells","presenterFirst":"Yves","presenterLast":"Baudat","presenterInstitution":"SANOFI","presenterCity":"vitry sur Seine","presenterCountry":"France","keywords":"Antitumor activity;Antibody drug conjugate;Antibody drug conjugate;NA","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"1183","name":"1183","title":"Optimal PEGylation of an auristatin linker provides ADCs with improved pharmacological properties","presenterFirst":"Patrick","presenterLast":"Burke","presenterInstitution":"Seattle Genetics, Inc.","presenterCity":"Bothell","presenterCountry":"United States","keywords":"Antitumor agents;Drug design;Drug design;Targeted drug delivery","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"1196","name":"1196","title":"Development of quaternary amine linkers for ADCs: Application to auristatin E and tubulysin","presenterFirst":"Patrick","presenterLast":"Burke","presenterInstitution":"Seattle Genetics, Inc.","presenterCity":"Bothell","presenterCountry":"United States","keywords":"Antitumor agents;Drug design;Drug design;Targeted drug delivery","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"1354","name":"1354","title":"A novel linker to enable alcohol-containing payloads for the preparation of antibody-drug conjugates","presenterFirst":"Robert","presenterLast":"Kolakowski","presenterInstitution":"Seattle Genetics","presenterCity":"Bothell","presenterCountry":"United States","keywords":"Drug delivery;Antitumor agents;Antitumor agents;Synthesis","category":"CANCER CHEMISTRY","sage":"ADC","moa":"NA"},{"id":"1415","name":"1415","title":"Tumor associated macrophages can process antibody-drug conjugates and contribute to antitumor activity in preclinical xenograft models","presenterFirst":"Fu","presenterLast":"Li","presenterInstitution":"Seattle Genetics","presenterCity":"Bothell","presenterCountry":"United States","keywords":"Tumor microenvironment;Macrophages;Macrophages;NA","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"1423","name":"1423","title":"SGN-CD352A: A novel humanized anti-CD352 antibody-drug conjugate for the treatment of multiple myeloma","presenterFirst":"Tim","presenterLast":"Lewis","presenterInstitution":"Seattle Genetics, Inc.","presenterCity":"Bothell","presenterCountry":"United States","keywords":"Multiple myeloma;Antibody drug conjugate;Antibody drug conjugate;Targeted therapy","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"1733","name":"1733","title":"Peptide-linked indolino-benzodiazepine DNA-alkylating agents for use in antibody-drug conjugates (ADCs)","presenterFirst":"Manami","presenterLast":"Shizuka","presenterInstitution":"ImmunoGen, Inc.","presenterCity":"Waltham","presenterCountry":"United States","keywords":"Antibody;DNA;DNA;NA","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"2902","name":"2902","title":"Potent <i>in vivo</i> activity of site-specific indolino-benzodiazepine antibody-drug conjugates (ADCs) generated via engineered cysteine conjugation","presenterFirst":"Nicholas","presenterLast":"Yoder","presenterInstitution":"ImmunoGen, Inc.","presenterCity":"Waltham","presenterCountry":"United States","keywords":"Antibody;Chemotherapy;Chemotherapy;Drug delivery","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"2926","name":"2926","title":"A novel PTK7-targeted antibody-drug conjugate eliminates tumor-initiating cells and induces sustained tumor regressions","presenterFirst":"Marc","presenterLast":"Damelin","presenterInstitution":"Pfizer, Inc.","presenterCity":"Pearl River","presenterCountry":"United States","keywords":"Drug discovery;Ovarian cancer;Ovarian cancer;Triple negative breast cancer","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"3149","name":"3149","title":"<i>In vitro</i> and <i>in vivo</i> activity of a site-specific SeriMab antibody-drug conjugate (ADC) using an indolino-benzodiazepine DNA-alkylating agent","presenterFirst":"Dilrukshi","presenterLast":"Vitharana","presenterInstitution":"ImmunoGen, Inc","presenterCity":"Waltham","presenterCountry":"United States","keywords":"Antitumor agents;NA;NA;NA","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"3212","name":"3212","title":"An anti-CD20 extracellular antibody-drug conjugate for the treatment of B-cell malignancies","presenterFirst":"James","presenterLast":"Prudent","presenterInstitution":"Centrose","presenterCity":"Madison","presenterCountry":"United States","keywords":"Antibody;Targeted drug delivery;Targeted drug delivery;Steroid hormones","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"3274","name":"3274","title":"<i>In vitro</i> and<i> in vivo</i> activity of site-specific antibody-drug conjugates (ADCs) with 2 and 4 maytansinoid molecules per antibody prepared through conjugation to SeriMabs (N-terminal serine engineered Abs)","presenterFirst":"Luke","presenterLast":"Harris","presenterInstitution":"ImmunoGen","presenterCity":"Waltham","presenterCountry":"United States","keywords":"Antitumor activity;Human monoclonal antibodies;Human monoclonal antibodies;NA","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"3775","name":"3775","title":"Development of a probody drug conjugate (PDC) targeting CD71 for the treatment of solid tumors and lymphomas","presenterFirst":"Shweta","presenterLast":"Singh","presenterInstitution":"CytomX Therapeutics","presenterCity":"South San Francisco","presenterCountry":"United States","keywords":"Antibody;Drug discovery;Drug discovery;Prodrugs","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"3812","name":"3812","title":"Metabolism studies of SH7139, a small molecule drug targeting B-cell malignancies overexpressing HLA-DR10, confirm its prodrug function","presenterFirst":"Monique","presenterLast":"Balhorn","presenterInstitution":"SHAL Technologies, Inc.","presenterCity":"Livermore","presenterCountry":"United States","keywords":"Non-Hodgkin's lymphoma;Metabolism;Metabolism;Cytotoxicity","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"3870","name":"3870","title":"Targeting GPNMB with 89Zr-CR011 for PET imaging of triple negative breast cancer","presenterFirst":"Bernadette","presenterLast":"Marquez","presenterInstitution":"Washington University School of Medicine","presenterCity":"Maplewood","presenterCountry":"United States","keywords":"Triple negative breast cancer;Antibody;Antibody;NA","category":"TUMOR BIOLOGY","sage":"ADC","moa":"NA"},{"id":"3900","name":"3900","title":"Inhibition of Rac1 GTPase activity by SH7139, a new drug candidate for non-Hodgkin&#8217;s lymphoma targeting HLA-DR10","presenterFirst":"Rodney","presenterLast":"Balhorn","presenterInstitution":"SHAL Technologies, Inc.","presenterCity":"Livermore","presenterCountry":"United States","keywords":"Non-Hodgkin's lymphoma;Therapeutics;Therapeutics;GTPase activating protein","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"3994","name":"3994","title":"Discovery and preclinical development of a highly potent NaPi2b-targeted antibody-drug conjugate (ADC) with significant activity in patient-derived non-small cell lung cancer (NSCLC) xenograft models","presenterFirst":"Natalya","presenterLast":"Bodyak","presenterInstitution":"Mersana Therapeutics","presenterCity":"Cambridge","presenterCountry":"United States","keywords":"Novel anticancer agents;NA;NA;NA","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"4348","name":"4348","title":"Targeting cadherin-6 (CDH6) with an antibody-drug conjugate for the treatment of ovarian and renal cancer.","presenterFirst":"Carl","presenterLast":"Bialucha","presenterInstitution":"Novartis Institutes for Biomedical Research","presenterCity":"Arlington","presenterCountry":"United States","keywords":"Ovarian cancer;Cadherin;Cadherin;Anticancer therapy","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"4539","name":"4539","title":"MEDI4276, a HER2-targeting antibody tubulysin conjugate, displays potent in<i> vitro </i>and <i>in vivo</i> activity in preclinical studies","presenterFirst":"Dorin","presenterLast":"Toader","presenterInstitution":"MedImmune LLC","presenterCity":"Gaithersburg","presenterCountry":"United States","keywords":"Antibody engineering;HER-2;HER-2;MEDI4276","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"3719","name":"3719","title":"Auristatin-based antibody drug conjugates activate multiple ER stress response pathways resulting in immunogenic cell death and amplified T-cell responses","presenterFirst":"Anthony","presenterLast":"Cao","presenterInstitution":"Seattle Genetics","presenterCity":"Bothell","presenterCountry":"United States","keywords":"UPR;Tumor immunity;Tumor immunity;Microtubules","category":"IMMUNOLOGY","sage":"ADC","moa":"NA"},{"id":"5140","name":"5140","title":"In vivo activity of a novel CDH6 targeting antibody-drug conjugate, including population-scale ovarian PDX clinical trial","presenterFirst":"Scott","presenterLast":"Collins","presenterInstitution":"Novartis Institutes for Biomedical Research","presenterCity":"Cambridge","presenterCountry":"United States","keywords":"Cadherin;Kidney cancer;Kidney cancer;In vivo","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"5428","name":"5428","title":"A novel antibody-drug conjugate directed to the ALK receptor tyrosine kinase demonstrates efficacy in models of neuroblastoma","presenterFirst":"Renata","presenterLast":"Sano","presenterInstitution":"Children's Hospital of Philadelphia","presenterCity":"Philadelphia","presenterCountry":"United States","keywords":"ALK;Antibody;Antibody;Resistance","category":"CLINICAL RESEARCH","sage":"ADC","moa":"NA"},{"id":"5702","name":"5702","title":"Preclinical development of 2nd generation HER2-directed antibody-drug conjugates","presenterFirst":"Gail","presenterLast":"Lewis Phillips","presenterInstitution":"Genentech, Inc.","presenterCity":"South San Francisco","presenterCountry":"United States","keywords":"HER-2;Anticancer therapy;Anticancer therapy;Targeted drug delivery","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"5755","name":"5755","title":"Anti-B7-H3 antibody-drug conjugates as potential therapeutics for solid cancer","presenterFirst":"Juniper","presenterLast":"Scribner","presenterInstitution":"MacroGenics, Inc.","presenterCity":"South San Francisco","presenterCountry":"United States","keywords":"Antibody engineering;Immunotherapy;Immunotherapy;Microtubule-interfering agents","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"5804","name":"5804","title":"Novel conditionally active biologic anti-Axl antibody-drug conjugate demonstrates anti-tumor efficacy and improved safety profile","presenterFirst":"Leslie","presenterLast":"Sharp","presenterInstitution":"BioAtla","presenterCity":"San Diego","presenterCountry":"United States","keywords":"Antibody;Targeted drug delivery;Targeted drug delivery;Receptor tyrosine kinase","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"6042","name":"6042","title":"Low molecular weight pyrrolobenzodiazepine (PBD) monomers have potent cytotoxicity in haematological malignancies","presenterFirst":"David","presenterLast":"Corcoran","presenterInstitution":"King's College London","presenterCity":"London","presenterCountry":"United Kingdom","keywords":"DNA adducts;Cytotoxicity;Cytotoxicity;Anticancer therapy","category":"CANCER CHEMISTRY","sage":"ADC","moa":"NA"},{"id":"6352","name":"6352","title":"Meditope enablement and structural analysis of anti-CD33 antibodies","presenterFirst":"Calin","presenterLast":"Dumitru","presenterInstitution":"TSRI","presenterCity":"San Diego","presenterCountry":"United States","keywords":"Acute myeloid leukemia;Antitumor agents;Antitumor agents;NA","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"6663","name":"6663","title":"A novel c-Met targeting antibody drug conjugate for NSCLC","presenterFirst":"Gang","presenterLast":"Chen","presenterInstitution":"Concortis Biosystems","presenterCity":"san diego","presenterCountry":"United States","keywords":"Anticancer therapy;c-Met;c-Met;Lung cancer: non-small cell","category":"CANCER CHEMISTRY","sage":"ADC","moa":"NA"},{"id":"6924","name":"6924","title":"High efficacy of BAY 1187982, an FGFR2-ADC, in overcoming drug resistance in a diffuse type gastric cancer patient-derived xenograft model with acquired resistance to pan-FGFR inhibitor AZD4547","presenterFirst":"Wen Min","presenterLast":"Lau","presenterInstitution":"Cancer Science Institute of Singapore","presenterCity":"Singapore","presenterCountry":"Singapore","keywords":"Drug resistance;diffuse-type gastric cancer;diffuse-type gastric cancer;FGFR2-ADC","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"7079","name":"7079","title":"Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates (ADCs) demonstrate tumor specificity, unique sequence homology and <i>in vitro</i> and <i>in vivo</i> antitumor efficacy","presenterFirst":"Jeff","presenterLast":"Behrens","presenterInstitution":"Siamab Therapeutics","presenterCity":"Newton","presenterCountry":"United States","keywords":"Antibody;ADC;ADC;Antibody Drug Conjugate","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"},{"id":"7086","name":"7086","title":"A dual-isotope 3D cryo-imaging quantitative autoradiography (CIQA) method for simultaneous and quantitative assessment of both antibody and drug conjugate tumor distribution and kinetics","presenterFirst":"Ohad","presenterLast":"Ilovich","presenterInstitution":"inviCRO","presenterCity":"Boston","presenterCountry":"United States","keywords":"Bystander effect;Molecular imaging;Molecular imaging;NA","category":"TUMOR BIOLOGY","sage":"ADC","moa":"NA"},{"id":"7136","name":"7136","title":"Labetuzumab govitecan (IMMU-130), an anti-CEACAM5/SN-38 antibody-drug conjugate, is active in patients (pts) with heavily pretreated metastatic colorectal cancer (mCRC): phase II results","presenterFirst":"Efrat","presenterLast":"Dotan","presenterInstitution":"Fox Chase Cancer Center","presenterCity":"Philadelphia","presenterCountry":"United States","keywords":"Colorectal cancer;carcinoembryonic antigen;carcinoembryonic antigen;clinical trial","category":"CLINICAL TRIALS","sage":"ADC","moa":"NA"},{"id":"7216","name":"7216","title":"Treatment for metastatic platinum-resistant urothelial cancer (PRUC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): phase I/II clinical experience","presenterFirst":"Scott","presenterLast":"Tagawa","presenterInstitution":"Weill Cornell Medicine","presenterCity":"New York","presenterCountry":"United States","keywords":"Genitourinary cancers: bladder;Trop-2;Trop-2;SN-38","category":"CLINICAL TRIALS","sage":"ADC","moa":"NA"},{"id":"7476","name":"7476","title":"Towards new cryptophycins as promising payloads for ADC","presenterFirst":"Marie-Priscille","presenterLast":"Brun","presenterInstitution":"Sanofi R&D","presenterCity":"Vitry-sur-Seine","presenterCountry":"France","keywords":"Targeted drug delivery;Cryptophycin;Cryptophycin;Payload","category":"CANCER CHEMISTRY","sage":"ADC","moa":"NA"},{"id":"7495","name":"7495","title":"A phase II trial of TAK-264, a novel antibody-drug conjugate (ADC), in patients with pancreatic adenocarcinoma expressing guanylyl cyclase C (GCC)","presenterFirst":"Khaldoun","presenterLast":"Almhanna","presenterInstitution":"Moffitt Cancer Center","presenterCity":"Tampa","presenterCountry":"United States","keywords":"Pancreatic cancer;Adenocarcinoma;Adenocarcinoma;Gastric cancer","category":"CLINICAL TRIALS","sage":"ADC","moa":"NA"},{"id":"7854","name":"7854","title":"An optide (optimized knottin-peptide) that inhibits tumor cell growth In vitro and accumulates in sarcoma flank tumors in vivo","presenterFirst":"James","presenterLast":"Olson","presenterInstitution":"Fred Hutchinson Cancer Center","presenterCity":"Seattle","presenterCountry":"United States","keywords":"Peptides;Targeted drug delivery;Targeted drug delivery;Antibody","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"ADC","moa":"NA"}]},{"id":"small","name":"small","presenterLast":"small","children":[{"id":"731","name":"731","title":"Actinomycin D enhanced immunotoxin RG7787 killing of cancer cells","presenterFirst":"Xiu Fen","presenterLast":"Liu","presenterInstitution":"NIH","presenterCity":"Bethesda","presenterCountry":"United States","keywords":"Apoptosis;NA;NA;NA","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"small","moa":"immune"},{"id":"1194","name":"1194","title":"Targeting immunosuppressive myeloid cells in oral cavity cancer with the PI3K&#948;/&#947; isoform inhibitor duvelisib","presenterFirst":"Ruth","presenterLast":"Davis","presenterInstitution":"Tumor Biology Section, Head and Neck Surgery Branch, National Institutes of Deafness and Other Communication Disorders, National Institutes of Health","presenterCity":"Bethesda","presenterCountry":"United States","keywords":"Immunomodulation;Myeloid-derived suppressor cells;Myeloid-derived suppressor cells;T-cell proliferation assay","category":"IMMUNOLOGY","sage":"small","moa":"immune"},{"id":"1336","name":"1336","title":"The BTK inhibitor ibrutinib modulates T cell immunity in mouse models and in differentiated human T cells","presenterFirst":"Yujun","presenterLast":"Huang","presenterInstitution":"Pharmacyclics LLC, an AbbVie Company","presenterCity":"Sunnyvale","presenterCountry":"United States","keywords":"Inhibitors;Lymphoma;Lymphoma;Immunomodulation","category":"IMMUNOLOGY","sage":"small","moa":"oncogenic kinases"},{"id":"1842","name":"1842","title":"Inhibition of liver inflammation and tumorigenesis by blocking Ccl2-Ccr2 axis in a mouse model","presenterFirst":"Kun-Yu","presenterLast":"Teng","presenterInstitution":"The Ohio State University","presenterCity":"Columbus","presenterCountry":"United States","keywords":"Hepatocellular carcinoma;MicroRNA-122;MicroRNA-122;NA","category":"IMMUNOLOGY","sage":"small","moa":"immune"},{"id":"1901","name":"1901","title":"A phase II trial of high-dose Interleukin-2 (HDIL-2) with recombinant MAGE-A3 protein combined with adjuvant system AS15 in patients with unresectable or metastatic melanoma","presenterFirst":"Jennifer","presenterLast":"McQuade","presenterInstitution":"UT MD Anderson Cancer Center","presenterCity":"Houston","presenterCountry":"United States","keywords":"Melanoma/skin cancers;Immunostimulation;Immunostimulation;Interleukin-2","category":"IMMUNOLOGY","sage":"small","moa":"immune"},{"id":"3143","name":"3143","title":"Engineering next-generation anti-CD25 immunotoxins with improved cytotoxic activity and low immunogenicity","presenterFirst":"Gilad","presenterLast":"Kaplan","presenterInstitution":"National Cancer Institute, NIH","presenterCity":"Bethesda","presenterCountry":"United States","keywords":"Immunotoxin;Therapeutic proteins;Therapeutic proteins;NA","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"small","moa":"immune"},{"id":"3374","name":"3374","title":"ROR&#947; agonists regulate immune checkpoint receptors to enhance anti-tumor immunity","presenterFirst":"Laura","presenterLast":"Carter","presenterInstitution":"Lycera Corp","presenterCity":"Ann Arbor","presenterCountry":"United States","keywords":"Immunotherapy;Small molecule drugs;Small molecule drugs;Antitumor activity","category":"IMMUNOLOGY","sage":"small","moa":"immune"},{"id":"4362","name":"4362","title":"Metformin improves multiple cytokine producing ability of exhausted peripheral CD8+ T cells of cancer patients","presenterFirst":"Mototsugu","presenterLast":"Watanabe","presenterInstitution":"Okayama University Graduate School of Medicine","presenterCity":"Okayama","presenterCountry":"Japan","keywords":"Cytotoxic T cell;Glycolysis;Glycolysis;NA","category":"IMMUNOLOGY","sage":"small","moa":"other"},{"id":"4554","name":"4554","title":"Discovery of novel and potent inhibitors of indoleamine-2,3-dioxygenase (IDO1) for cancer immunotherapy","presenterFirst":"Qun","presenterLast":"Li","presenterInstitution":"Shanghai Denovo Pharmatech","presenterCity":"Zhangjiang New Area, Shanghai","presenterCountry":"China","keywords":"Immunotherapy;indoleamine-2,3-dioxygenase;indoleamine-2,3-dioxygenase;TDO","category":"IMMUNOLOGY","sage":"small","moa":"immune"},{"id":"4633","name":"4633","title":"The reduced immunogenicity anti-mesothelin immunotoxin RG7787 in combination with nab-paclitaxel has significant anti-tumor efficacy against primary mesothelioma cell lines and patient derived mesothelioma tumor xenografts","presenterFirst":"Jingli","presenterLast":"Zhang","presenterInstitution":"National Cancer Institute","presenterCity":"Bethesda","presenterCountry":"United States","keywords":"Mesothelioma;Nab-Paclitaxel;Nab-Paclitaxel;Mesothelin","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"small","moa":"immune"},{"id":"4824","name":"4824","title":"Epigenetic induction of MHC-II pathway expression in murine ovarian cancer cell line","presenterFirst":"Rebecca","presenterLast":"Arend","presenterInstitution":"University of Alabama Birmingham","presenterCity":"Birmingham","presenterCountry":"United States","keywords":"Ovarian cancer;MHC II;MHC II;Histone deacetylase inhibitor","category":"IMMUNOLOGY","sage":"small","moa":"epigenetics"},{"id":"4878","name":"4878","title":"Immuno-oncology agent CB-1158 is a potent and selective arginase inhibitor and causes an immune-mediated anti-tumor response","presenterFirst":"Melissa","presenterLast":"Works","presenterInstitution":"Calithera Biosciences","presenterCity":"South San Francisco","presenterCountry":"United States","keywords":"Immunomodulation;Tumor immunity;Tumor immunity;NA","category":"IMMUNOLOGY","sage":"small","moa":"immune"},{"id":"5145","name":"5145","title":"MT-3724, an engineered toxin body targeting CD20 for non-Hodgkin&#8217;s lymphoma","presenterFirst":"Garrett","presenterLast":"Robinson","presenterInstitution":"Molecular Templates Inc.","presenterCity":"Georgetown","presenterCountry":"United States","keywords":"Immunotoxin;Immunotherapy;Immunotherapy;Non-Hodgkin's lymphoma","category":"IMMUNOLOGY","sage":"small","moa":"immune"},{"id":"5267","name":"5267","title":"Enzymatic depletion of adenosine by pegylated, engineered adenosine deaminase 2 (PEG-ADA2): A novel immunotherapeutic approach to treat solid tumors","presenterFirst":"Christopher","presenterLast":"Thanos","presenterInstitution":"Halozyme Therapeutics","presenterCity":"San Diego","presenterCountry":"United States","keywords":"Immunotherapy;Immunomodulation;Immunomodulation;Checkpoint","category":"IMMUNOLOGY","sage":"small","moa":"immune"},{"id":"5307","name":"5307","title":"Next-generation engineered toxin bodies: CD38, PD-L1 and HER2 targeted ETBs","presenterFirst":"Sangeetha","presenterLast":"Rajagopalan","presenterInstitution":"Molecular Templates Inc.","presenterCity":"Georgetown","presenterCountry":"United States","keywords":"Immunotoxin;Immunotherapy;Immunotherapy;Antibody engineering","category":"IMMUNOLOGY","sage":"small","moa":"immune"},{"id":"5371","name":"5371","title":"Small molecule inhibitors of the anti-inflammatory TAM receptor MerTK","presenterFirst":"Sacha","presenterLast":"Holland","presenterInstitution":"Rigel Pharmaceuticals, Inc.","presenterCity":"S. San Francisco","presenterCountry":"United States","keywords":"Immune response;Receptor tyrosine kinase inhibitor;Receptor tyrosine kinase inhibitor;NA","category":"IMMUNOLOGY","sage":"small","moa":"immune"},{"id":"5596","name":"5596","title":"Cbl-b inhibitors as novel intra-cellular checkpoint inhibitors for cancer immunotherapy","presenterFirst":"Saket","presenterLast":"Agarwal","presenterInstitution":"Progenra Inc","presenterCity":"Malvern","presenterCountry":"United States","keywords":"Ubiquitination;NA;NA;Tumor immunity","category":"CLINICAL RESEARCH","sage":"small","moa":"immune"},{"id":"5696","name":"5696","title":"Developing a novel immunotoxin that targets cells overexpressing ErbB2","presenterFirst":"Luqun","presenterLast":"Shen","presenterInstitution":"University of Notre Dame","presenterCity":"Notre Dame","presenterCountry":"United States","keywords":"Immunotoxin;Breast cancer;Breast cancer;Cell death","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"small","moa":"immune"},{"id":"6077","name":"6077","title":"Vaccination enhances anti-tumor immunity in ovarian cancer following repolarization of the tumor microenvironment with CCR2 blockade","presenterFirst":"Darren","presenterLast":"Cullinan","presenterInstitution":"Washington University","presenterCity":"Saint Louis","presenterCountry":"United States","keywords":"Ovarian cancer;Chemokine receptor;Chemokine receptor;Vaccines","category":"IMMUNOLOGY","sage":"small","moa":"immune"},{"id":"6384","name":"6384","title":"Inhibition of adenosine A2A receptor (A2AR) by CPI-444 enhances CD8+ T cell killing of a HER-2/neu expressing murine tumor","presenterFirst":"Blake","presenterLast":"Scott","presenterInstitution":"Johns Hopkins University School of Medicine","presenterCity":"Baltimore","presenterCountry":"United States","keywords":"Checkpoint;T cell;T cell;Tumor immunity","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"small","moa":"immune"},{"id":"6405","name":"6405","title":"STING activation in the tumor microenvironment with a synthetic human STING-activating cyclic dinucleotide leads to potent anti-tumor immunity","presenterFirst":"Laura","presenterLast":"Glickman","presenterInstitution":"Aduro Biotech, Inc.","presenterCity":"Berkeley","presenterCountry":"United States","keywords":"Interferons;Innate immunity;Innate immunity;T cell","category":"IMMUNOLOGY","sage":"small","moa":"immune"},{"id":"6481","name":"6481","title":"Development of a novel class of traps that potently block transforming growth factor-beta (TGF-beta) thereby counteracting TGF-beta mediated immunosuppression and promoting T-cell infiltration into tumors","presenterFirst":"Maureen","presenterLast":"O'Connor-McCourt","presenterInstitution":"Formation Biologics","presenterCity":"Montreal","presenterCountry":"Canada","keywords":"Immunotherapy;T cell;T cell;Tumor microenvironment","category":"IMMUNOLOGY","sage":"small","moa":"immune"},{"id":"6608","name":"6608","title":"Increased IgG antibody responses to neoepitope and native peptides containing high affinity domains for MHCI following combination cancer immunotherapy","presenterFirst":"Tyler","presenterLast":"Hulett","presenterInstitution":"Oregon Health & Science University","presenterCity":"Portland","presenterCountry":"United States","keywords":"Antibody;Vaccines;Vaccines;MHC I","category":"IMMUNOLOGY","sage":"small","moa":"immune"},{"id":"1329","name":"1329","title":"Pre-clinical development of next generation inhibitors of the enzymes indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase as cancer immunotherapies","presenterFirst":"Alan","presenterLast":"Wise","presenterInstitution":"IOmet Pharma Ltd","presenterCity":"Edinburgh","presenterCountry":"United Kingdom","keywords":"Immunotherapy;Immunomodulation;Immunomodulation;IDO1","category":"TUMOR BIOLOGY","sage":"small","moa":"immune"},{"id":"3190","name":"3190","title":"Repurposing the FDA-approved drug carbidopa to treat human cancers","presenterFirst":"Vadivel","presenterLast":"Ganapathy","presenterInstitution":"Texas Tech University Health Science Center","presenterCity":"Lubbock","presenterCountry":"United States","keywords":"Breast cancer;Carbidopa;Carbidopa;Antitumor effect","category":"MOLECULAR AND CELLULAR BIOLOGY, GENETICS","sage":"small","moa":"immune"},{"id":"4799","name":"4799","title":"Creating the tumor microenvironment for effective immunotherapy: Antitumor activity of intratumoral IMO-2125, a TLR9 agonist is further enhanced by inhibition of indoleamine-pyrrole 2,3-dioxygenase (IDO)","presenterFirst":"Daqing","presenterLast":"Wang","presenterInstitution":"Idera Pharmaceuticals, Inc.","presenterCity":"Cambridge","presenterCountry":"United States","keywords":"Immunotherapy;Checkpoint;Checkpoint;Immunomodulation","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"small","moa":"immune"},{"id":"6311","name":"6311","title":"Alpha-tocopheryloxyacetic acid (aTEA) induced immune activation synergizes with radiation therapy to treat primary and metastatic murine mammary carcinoma","presenterFirst":"Joshua","presenterLast":"Walker","presenterInstitution":"Oregon Health & Science University","presenterCity":"Portland","presenterCountry":"United States","keywords":"Radiation therapy;T cell;T cell;Breast cancer","category":"TUMOR BIOLOGY","sage":"small","moa":"immune"},{"id":"4157","name":"4157","title":"The amphiphatic &#946;(2,2)-amino acid derivative, LTX-401 induces complete regression of experimental hepatocellular carcinomas","presenterFirst":"Brynjar","presenterLast":"Mauseth","presenterInstitution":"Department of Medical Biology, University of Troms\u00f8","presenterCity":"TROMS\u00d8","presenterCountry":"Norway","keywords":"Cancer;Hepatocellular carcinoma;Hepatocellular carcinoma;Inflammation","category":"IMMUNOLOGY","sage":"small","moa":"immune"},{"id":"5642","name":"5642","title":"Imprime PGG synergizes with anti-angiogenic antibodies to repolarize the immune microenvironment, suppressing xenograft tumor growth <i>in vivo</i>","presenterFirst":"Kathryn","presenterLast":"Fraser","presenterInstitution":"Biothera","presenterCity":"Eagan","presenterCountry":"United States","keywords":"Angiogenesis inhibitor;Innate immunity;Innate immunity;Immunostimulation","category":"TUMOR BIOLOGY","sage":"small","moa":"immune"},{"id":"2209","name":"2209","title":"A novel multidrug metronomic chemotherapy significantly delays tumor growth in mice","presenterFirst":"Luigi","presenterLast":"Buonaguro","presenterInstitution":"National Cancer Institute","presenterCity":"NAPLES","presenterCountry":"Italy","keywords":"Microenvironment;Combination therapy;Combination therapy;Vaccines","category":"TUMOR BIOLOGY","sage":"small","moa":"chemotherapy"},{"id":"6713","name":"6713","title":"Tyrosine kinase discoidin domain receptor-1 (DDR1) regulates cytotoxicity of recombinant immunotoxin for cancer therapy","presenterFirst":"Fatima","presenterLast":"Ali-Rahmani","presenterInstitution":"National Cancer Institute","presenterCity":"Bethesda","presenterCountry":"United States","keywords":"Pancreatic cancer;Mesothelin;Mesothelin;DDR1","category":"TUMOR BIOLOGY","sage":"small","moa":"immune"},{"id":"6771","name":"6771","title":"Clinical application of a natural polypeptide, poly-&#947;-glutamic acid, which has immunotherapeutic efficacy","presenterFirst":"Jae-Kwan","presenterLast":"Lee","presenterInstitution":"Korea University Guro Hospital","presenterCity":"Seoul","presenterCountry":"Korea, Republic of","keywords":"Natural killer cells;NA;NA;NA","category":"CLINICAL TRIALS","sage":"small","moa":"immune"},{"id":"7014","name":"7014","title":"Novel intraperitoneal treatment for peritoneal metastases: results from the Immunotoxin in Peritoneal Carcinomatosis (ImmunoPeCa) phase I clinical trial","presenterFirst":"Kjersti","presenterLast":"Flatmark","presenterInstitution":"The Norwegian Radium Hospital, Oslo University Hospital","presenterCity":"Oslo","presenterCountry":"Norway","keywords":"Immunotoxin;Peritoneal metastasis;Peritoneal metastasis;Hyperthermic intraperitoneal chemotherapy","category":"CLINICAL TRIALS","sage":"small","moa":"immune"},{"id":"7279","name":"7279","title":"Phase I/Ib study of the novel CD20-targeted immunotoxin MT-3724 in relapsed/refractory non-Hodgkin's B-cell lymphoma","presenterFirst":"Michelle","presenterLast":"Fanale","presenterInstitution":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center","presenterCity":"Houston","presenterCountry":"United States","keywords":"Lymphoma: non-Hodgkin's lymphoma;Phase 1;Phase 1;NA","category":"CLINICAL TRIALS","sage":"small","moa":"immune"},{"id":"7290","name":"7290","title":"RG70099: A novel, highly potent dual IDO1/TDO inhibitor to reverse metabolic suppression of immune cells in the tumor micro-environment","presenterFirst":"Gabor","presenterLast":"Gyulveszi","presenterInstitution":"Roche pRED, Roche Innovation Center Zurich","presenterCity":"Schlieren","presenterCountry":"Switzerland","keywords":"Immunotherapy;NA;NA;NA","category":"IMMUNOLOGY","sage":"small","moa":"immune"},{"id":"7880","name":"7880","title":"Imprime PGG, a &#946;-glucan PAMP (pathogen-associated molecular pattern) activates the direct killing functions of innate immune cells in concert with tumor targeting antibodies","presenterFirst":"Steven","presenterLast":"Leonardo","presenterInstitution":"Biothera Pharmaceutical Inc","presenterCity":"Eagan","presenterCountry":"United States","keywords":"Immunotherapy;Immunomodulation;Immunomodulation;Monoclonal antibodies","category":"IMMUNOLOGY","sage":"small","moa":"immune"},{"id":"7940","name":"7940","title":"Imprime PGG, a &#946;-glucan PAMP (pathogen-associated molecular pattern), effectively elicits in vivo maturation of antigen presenting cells in mice and humans, suggesting potential synergy with checkpoint inhibitor therapy","presenterFirst":"Ross","presenterLast":"Fulton","presenterInstitution":"Biothera, Inc.","presenterCity":"Eagan","presenterCountry":"United States","keywords":"Dendritic cells;Monocyte;Monocyte;Anticancer therapy","category":"IMMUNOLOGY","sage":"small","moa":"immune"},{"id":"1257","name":"1257","title":"Toll like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancer","presenterFirst":"Radhashree","presenterLast":"Maitra","presenterInstitution":"Montefiore Medical Center","presenterCity":"Bronx","presenterCountry":"United States","keywords":"Colorectal cancer;NA;NA;NA","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"small","moa":"immune"},{"id":"2394","name":"2394","title":"Cancer cell-mediated signaling of TLR 2, 4, and 9 causes activation of PI3K/Akt/mTOR pathway and induces tumor cell proliferation in pancreatic cancer","presenterFirst":"Ana Maria","presenterLast":"Waaga-Gasser","presenterInstitution":"University of Wuerzburg, Dept. of Surgery I, Molecular Oncology and Immunology","presenterCity":"Wuerzburg","presenterCountry":"Germany","keywords":"Pancreatic cancer;NA;NA;NA","category":"IMMUNOLOGY","sage":"small","moa":"immune"},{"id":"4062","name":"4062","title":"Toll-like receptor expression and ligation promotes in vitro invasion in pancreatic cancer","presenterFirst":"Ibtehaj","presenterLast":"Naqvi","presenterInstitution":"Duke University Medical School","presenterCity":"Durham","presenterCountry":"United States","keywords":"Pancreatic cancer;Tumor microenvironment;Tumor microenvironment;NA","category":"MOLECULAR AND CELLULAR BIOLOGY, GENETICS","sage":"small","moa":"immune"},{"id":"5703","name":"5703","title":"Myelosuppression in patients treated with the telomerase inhibitor imetelstat is not mediated through activation of toll-like receptors","presenterFirst":"Gabriela","presenterLast":"Baerlocher","presenterInstitution":"Inselspital/University Hospital of Bern","presenterCity":"CH-3010 Bern","presenterCountry":"Switzerland","keywords":"Telomerase;Antisense oligonucleotides;Antisense oligonucleotides;NA","category":"MOLECULAR AND CELLULAR BIOLOGY, GENETICS","sage":"small","moa":"immune"},{"id":"1320","name":"1320","title":"Regulation of MDSC trafficking and function in RCC by CXCR4 in the presence of a VEGF-R antagonist","presenterFirst":"David","presenterLast":"Panka","presenterInstitution":"Beth Israel Deaconess Med Ctr","presenterCity":"Boston","presenterCountry":"United States","keywords":"CXCR4;Resistance;Resistance;Renal cell carcinoma","category":"TUMOR BIOLOGY","sage":"small","moa":"immune"},{"id":"2151","name":"2151","title":"Hypoxia as a driver of myeloid-derived suppressor cell recruitment in hepatocellular carcinoma via CCL26/CX3CR1","presenterFirst":"David Kung-Chun","presenterLast":"Chiu","presenterInstitution":"The University of Hong Kong","presenterCity":"Hong Kong","presenterCountry":"Hong Kong","keywords":"Hepatocellular carcinoma;NA;NA;NA","category":"TUMOR BIOLOGY","sage":"small","moa":"immune"},{"id":"4466","name":"4466","title":"Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression","presenterFirst":"Sun-Hee","presenterLast":"Kim","presenterInstitution":"UT MD Anderson Cancer Center","presenterCity":"Houston","presenterCountry":"United States","keywords":"Prostaglandin E2;iNOS;iNOS;Inflammation","category":"CLINICAL RESEARCH","sage":"small","moa":"immune"},{"id":"4685","name":"4685","title":"Aminoflavone acts as an immunomodulator of tumor growth in a breast cancer mouse model","presenterFirst":"Mariana","presenterLast":"Callero","presenterInstitution":"Angel H. Roffo Inst. of Oncology","presenterCity":"Buenos Aires","presenterCountry":"Argentina","keywords":"Immunomodulation;Breast cancer;Breast cancer;NA","category":"CLINICAL RESEARCH","sage":"small","moa":"immune"},{"id":"3620","name":"3620","title":"Macrophage PI3Kgamma signaling promotes cancer immune suppression","presenterFirst":"Megan","presenterLast":"Kaneda","presenterInstitution":"UCSD Moores Cancer Center","presenterCity":"La Jolla","presenterCountry":"United States","keywords":"PI3K;T cell;T cell;NF-&#954;B","category":"TUMOR BIOLOGY","sage":"small","moa":"leucocyte kinases"}]},{"id":"small combo ADC","name":"small combo ADC","presenterLast":"small combo ADC","children":[{"id":"3815","name":"3815","title":"CRLX101, an investigational nanoparticle-drug conjugate of camptothecin, demonstrates synergy with immunotherapy agents in preclinical models","presenterFirst":"Douglas","presenterLast":"Lazarus","presenterInstitution":"Cerulean Pharma, Inc.","presenterCity":"Walthem","presenterCountry":"United States","keywords":"Nanoparticle;Topoisomerase I inhibitor;Topoisomerase I inhibitor;Checkpoint","category":"IMMUNOLOGY","sage":"small combo ADC","moa":"immune"},{"id":"5425","name":"5425","title":"Significant enhancement of efficacy of an anti-Trop-2 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), in experimental triple-negative breast cancer (TNBC) when combined with microtubule or PARP inhibitors","presenterFirst":"David","presenterLast":"Goldenberg","presenterInstitution":"Immunomedics, Inc.","presenterCity":"Morris Plains","presenterCountry":"United States","keywords":"Targeted drug delivery;PARP;PARP;Trop-2","category":"IMMUNOLOGY","sage":"small combo ADC","moa":"oncogenic kinases"},{"id":"3686","name":"3686","title":"Preclinical combinations of the antibody-drug conjugate SGN-LIV1A with chemotherapies show increased activity","presenterFirst":"Django","presenterLast":"Sussman","presenterInstitution":"Seattle Genetics","presenterCity":"Bothell","presenterCountry":"United States","keywords":"Antibody;Drug synergy;Drug synergy;NA","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"small combo ADC","moa":"chemotherapy"}]},{"id":"small combo CPI","name":"small combo CPI","presenterLast":"small combo CPI","children":[{"id":"835","name":"835","title":"The immune modulatory roles of IAP inhibitor, LCL161, and its connection to immune-checkpoint molecules","presenterFirst":"Z. Alexander","presenterLast":"Cao","presenterInstitution":"Novartis","presenterCity":"Cambridge","presenterCountry":"United States","keywords":"IAP;NA;NA;NA","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"872","name":"872","title":"Assessing and augmenting the immune response to glioblastoma using repurposed pharmaceuticals","presenterFirst":"Breanna","presenterLast":"Brenneman","presenterInstitution":"University of Virginia","presenterCity":"Charlottesville","presenterCountry":"United States","keywords":"Brain/central nervous system cancers;Immune response;Immune response;Synergism","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"1221","name":"1221","title":"PEGylated recombinant hyaluronidase PH20 (PEGPH20) enhances checkpoint inhibitor efficacy in syngeneic mouse models of cancer","presenterFirst":"Sanna","presenterLast":"Rosengren","presenterInstitution":"Halozyme Therapeutics","presenterCity":"San Diego","presenterCountry":"United States","keywords":"Hyaluronan;PD-1 blockade;PD-1 blockade;Anti-CTLA4","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"1311","name":"1311","title":"Ibrutinib enhances antitumor activity in solid tumors when combined with checkpoint inhibitors","presenterFirst":"Jeff","presenterLast":"Hsu","presenterInstitution":"Pharmacyclics LLC, an AbbVie Company","presenterCity":"Sunnyvale","presenterCountry":"United States","keywords":"Immunomodulation;Mouse models;Mouse models;Immunotherapy","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"1330","name":"1330","title":"PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors","presenterFirst":"Manfred","presenterLast":"Kraus","presenterInstitution":"Pfizer","presenterCity":"San Diego","presenterCountry":"United States","keywords":"Cancer immunotherapy;Checkpoint;Checkpoint;T lymphocytes","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"1386","name":"1386","title":"Ibrutinib, a BTK inhibitor, impairs the generation and function of myeloid derived suppressor cells","presenterFirst":"Andrew","presenterLast":"Stiff","presenterInstitution":"The Ohio State University","presenterCity":"Columbus","presenterCountry":"United States","keywords":"Immunomodulation;Ibrutinib;Ibrutinib;Breast cancer","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"oncogenic kinases"},{"id":"1473","name":"1473","title":"Epigenetic changes in T cells in response to immune checkpoint blockade","presenterFirst":"Sangeeta","presenterLast":"Goswami","presenterInstitution":"MD Anderson Cancer Center","presenterCity":"Katy","presenterCountry":"United States","keywords":"Histone modification;Immunotherapy;Immunotherapy;Checkpoint","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"epigenetics"},{"id":"1615","name":"1615","title":"Local immune activation resulting in tumor growth inhibition with MEDI9197 - an intratumorally administered TLR7/8 agonist","presenterFirst":"Andrew","presenterLast":"Leishman","presenterInstitution":"MedImmune","presenterCity":"Cambridge","presenterCountry":"United Kingdom","keywords":"Immunomodulation;TLR7;TLR7;TLR8","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"2178","name":"2178","title":"Combined treatment with PD-L1 blockade and a TLR7/8 agonist dramatically enhances antitumor immunity","presenterFirst":"Naoto","presenterLast":"Nishii","presenterInstitution":"Department of Molecular Immunology, Tokyo Medical and Dental University","presenterCity":"Tokyo","presenterCountry":"Japan","keywords":"Cancer immunotherapy;Immune checkpoints;Immune checkpoints;PD-L1","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"2499","name":"2499","title":"LTX-315, an oncolytic peptide, increases anticancer immunity mediated by CTLA4 blockade in an interleukin-2 receptor beta-chain-dependent manner","presenterFirst":"Takahiro","presenterLast":"Yamazaki","presenterInstitution":"Gustave Roussy Cancer Campus","presenterCity":"VILLEJUIF","presenterCountry":"France","keywords":"Cancer immunotherapy;Antimicrobial peptides;Antimicrobial peptides;Immunogenic cell death","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"2534","name":"2534","title":"Effective <i>in situ</i> immunization via local radiation therapy (RT) and tumor-specific immunocytokine (IC): Suppression from distant tumor is blocked by RT or Treg-depleting CTLA-4 antibody","presenterFirst":"Paul","presenterLast":"Sondel","presenterInstitution":"University of Wisconsin","presenterCity":"Madison","presenterCountry":"United States","keywords":"Immunotherapy;Radiation therapy;Radiation therapy;Combination therapy","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"2540","name":"2540","title":"AGI-134: a fully synthetic alpha-Gal glycolipid that prevents the development of distal lesions and is synergistic with an anti-PD-1 antibody in a mouse melanoma model","presenterFirst":"Stephen","presenterLast":"Shaw","presenterInstitution":"Agalimmune Ltd","presenterCity":"Sandwich","presenterCountry":"United Kingdom","keywords":"Antitumor agents;Combination studies;Combination studies;Synergism","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"2855","name":"2855","title":"Multimodal therapy with a potent vaccine, metronomic cyclophosphamide and anti-PD-1 enhances immunotherapy of advanced tumors by increasing activation and clonal expansion of tumor infiltrating T cells","presenterFirst":"Genevieve","presenterLast":"Weir","presenterInstitution":"Immunovaccine Inc.","presenterCity":"Halifax","presenterCountry":"Canada","keywords":"Vaccines;Cyclophosphamide;Cyclophosphamide;Checkpoint","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"chemotherapy"},{"id":"2986","name":"2986","title":"FAK/PYK2 inhibition enhances immune checkpoint inhibitor efficacy","presenterFirst":"Yan","presenterLast":"Wang","presenterInstitution":"Verastem","presenterCity":"Needham","presenterCountry":"United States","keywords":"FAK;PD-1;PD-1;NA","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"oncogenic kinases"},{"id":"3057","name":"3057","title":"CXCL12 inhibition with NOX-A12 (olaptesed pegol) increases T-cell infiltration in tumor-stroma spheroids and synergizes with PD-1 immune checkpoint blockade","presenterFirst":"Dirk","presenterLast":"Zboralski","presenterInstitution":"NOXXON Pharma","presenterCity":"Berlin","presenterCountry":"Germany","keywords":"CXCR4;Immunotherapy;Immunotherapy;Spheroids","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"3298","name":"3298","title":"Combination therapy of chemokine receptor inhibition plus PD-L1 blockade potentiates antitumor effects in a murine model of breast cancer","presenterFirst":"Heiyoun","presenterLast":"Jung","presenterInstitution":"ChemoCentryx","presenterCity":"Mountain View","presenterCountry":"United States","keywords":"Immunotherapy;Checkpoint;Checkpoint;Small molecule inhibitor","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"3431","name":"3431","title":"Inhibiting DNA methylation causes an interferon response in cancer cells via endogenous retroviruses and recruits immune cells to the tumor microenvironment to sensitize to immune therapy","presenterFirst":"Katherine","presenterLast":"Chiappinelli","presenterInstitution":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins School of Medicine","presenterCity":"Baltimore","presenterCountry":"United States","keywords":"Epigenetics;DNA methylation;DNA methylation;Immunotherapy","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"epigenetics"},{"id":"3515","name":"3515","title":"Enhancing the antitumor efficacy of immunotherapy by using the topoisomerase I inhibitor MM398","presenterFirst":"Jodi","presenterLast":"McKenzie","presenterInstitution":"The University of Texas MD Anderson Cancer Center","presenterCity":"Houston","presenterCountry":"United States","keywords":"Cancer immunotherapy;Melanoma/skin cancers;Melanoma/skin cancers;Immunomodulation","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"chemotherapy"},{"id":"3530","name":"3530","title":"The BET inhibitor INCB054329 enhances the activity of checkpoint modulation in syngeneic tumor models","presenterFirst":"Holly","presenterLast":"Koblish","presenterInstitution":"Incyte Corporation","presenterCity":"Wilmington","presenterCountry":"United States","keywords":"Checkpoint;IDO1 inhibitors;IDO1 inhibitors;NA","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"oncogenic kinases"},{"id":"3585","name":"3585","title":"Epigenetic treatment of ovarian cancer cells increases immune cell recruitment to the tumor microenvironment: implications for response to immune checkpoint therapy","presenterFirst":"Meredith","presenterLast":"Stone","presenterInstitution":"Johns Hopkins School of Medicine","presenterCity":"Baltimore","presenterCountry":"United States","keywords":"Epigenetics;Ovarian cancer;Ovarian cancer;Preclinical","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"epigenetics"},{"id":"3637","name":"3637","title":"The adenosine A2A receptor antagonist CPI-444 blocks adenosine-mediated T-cell suppression and exhibits antitumor activity alone and in combination with anti-PD-1 and anti-PD-L1","presenterFirst":"Stephen","presenterLast":"Willingham","presenterInstitution":"Corvus Pharmaceuticals","presenterCity":"Burlingame","presenterCountry":"United States","keywords":"Immunotherapy;Adenosine;Adenosine;T cell","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"3654","name":"3654","title":"Development of a successful combination therapy for hepatocellular cancer by targeting Treg and PD-1","presenterFirst":"Dai","presenterLast":"Liu","presenterInstitution":"Medical University of South Carolina","presenterCity":"Charleston","presenterCountry":"United States","keywords":"Hepatocellular carcinoma;Regulatory T cells;Regulatory T cells;Checkpoint","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"oncogenic kinases"},{"id":"3664","name":"3664","title":"Elevated immune activity following an anticancer combination therapy of a novel oncolytic immunotherapeutic agent, CAVATAK (Coxsackievirus A21), and immune checkpoint blockade","presenterFirst":"Darren","presenterLast":"Shafren","presenterInstitution":"Viralytics Limited","presenterCity":"New Lambton","presenterCountry":"Australia","keywords":"Immunotherapy;Checkpoint;Checkpoint;NA","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"3806","name":"3806","title":"The class I HDAC inhibitor, mocetinostat, induces expression of PD-L1 and tumor antigen presentation machinery and modifies tumor immune cellular subsets providing a rationale for immune checkpoint inhibitor combinations","presenterFirst":"David","presenterLast":"Briere","presenterInstitution":"Mirati Therapeutics, Inc.","presenterCity":"San Diego","presenterCountry":"United States","keywords":"Lung cancer: non-small cell;Epigenetics;Epigenetics;Immunotherapy","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"epigenetics"},{"id":"3967","name":"3967","title":"Combination therapy with immune checkpoint inhibitor and CCK-receptor blockade increases survival of pancreatic cancer","presenterFirst":"Jill","presenterLast":"Smith","presenterInstitution":"Georgetown University","presenterCity":"Washington","presenterCountry":"United States","keywords":"Receptors;Microenvironment;Microenvironment;Immunotherapy","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"4005","name":"4005","title":"In situ vaccination with TLR9 agonist and anti-Ox40 antibody is sufficient to induce abscopal responses even in mice with spontaneous oncogene-driven tumors.","presenterFirst":"Idit","presenterLast":"Sagiv-Barfi","presenterInstitution":"Stanford University","presenterCity":"Stanford","presenterCountry":"United States","keywords":"Immunotherapy;NA;NA;NA","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"4018","name":"4018","title":"Immunogenic chemotherapy synergize PD-1 blockade by enhancing dendritic cells infiltration in triple-negative breast cancer (TNBC)","presenterFirst":"Xiangliang","presenterLast":"Yuan","presenterInstitution":"The University of Texas M. D. Anderson Cancer Center","presenterCity":"Houston","presenterCountry":"United States","keywords":"Immunotherapy;Microenvironment;Microenvironment;Breast cancer","category":"CLINICAL RESEARCH","sage":"small combo CPI","moa":"chemotherapy"},{"id":"4022","name":"4022","title":"Clinical activity and immune correlates from a phase Ib study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic colorectal carcinoma","presenterFirst":"Jeffrey","presenterLast":"Wallin","presenterInstitution":"Genentech, Inc.","presenterCity":"San Francisco","presenterCountry":"United States","keywords":"Cancer immunotherapy;Angiogenesis;Angiogenesis;Biomarker","category":"CLINICAL RESEARCH","sage":"small combo CPI","moa":"chemotherapy"},{"id":"4045","name":"4045","title":"Intratumoral treatment with a highly interferogenic TLR9 agonist reverts tumor escape from PD-1 blockade","presenterFirst":"Cristiana","presenterLast":"Guiducci","presenterInstitution":"Dynavax Technologies","presenterCity":"Berkeley","presenterCountry":"United States","keywords":"Immunotherapy;NA;NA;NA","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"4228","name":"4228","title":"Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment","presenterFirst":"Anna","presenterLast":"Dimberg","presenterInstitution":"Uppsala University","presenterCity":"Uppsala","presenterCountry":"Sweden","keywords":"CD40;MDSC;MDSC;Endothelial activation","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"oncogenic kinases"},{"id":"4266","name":"4266","title":"Antitumor activity of the oncolytic peptide LTX-315 in syngeneic tumor models","presenterFirst":"Sylvie","presenterLast":"Maubant","presenterInstitution":"Oncodesign S.A.","presenterCity":"Dijon","presenterCountry":"France","keywords":"Anticancer therapy;Mouse models;Mouse models;Peptides","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"small combo CPI","moa":"immune"},{"id":"4286","name":"4286","title":"Boosting immunotherapy via stealthy nanoparticle-mediated photothermal therapy","presenterFirst":"Hongwei","presenterLast":"Chen","presenterInstitution":"University of Michigan","presenterCity":"Ann Arbor","presenterCountry":"United States","keywords":"Immune response;Metastasis;Metastasis;Hyperthermia","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"4545","name":"4545","title":"Targeting the TGF&#946; pathway with galunisertib, a small molecule inhibitor of TGF&#946;RI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition.","presenterFirst":"David","presenterLast":"Schaer","presenterInstitution":"Eli Lilly and Company","presenterCity":"New York","presenterCountry":"United States","keywords":"TGF-&#946;;Immunotherapy;Immunotherapy;Combination therapy","category":"CLINICAL RESEARCH","sage":"small combo CPI","moa":"immune"},{"id":"4575","name":"4575","title":"Adenosine A2a receptor blockade as a means of enhancing immune checkpoint inhibition and adoptive T-cell therapy","presenterFirst":"Robert","presenterLast":"Leone","presenterInstitution":"Sidney Kimmel Comprehensive Cancer Research Center, Johns Hopkins University School of Medicine","presenterCity":"Baltimore","presenterCountry":"United States","keywords":"Immunotherapy;Adoptive immunotherapy;Adoptive immunotherapy;A2a","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"4657","name":"4657","title":"Imprime PGG triggers PD-L1 expression on tumor and myeloid cells and prevents tumor establishment in combination with &#945;PD-L1 treatment in vivo","presenterFirst":"Kathryn","presenterLast":"Fraser","presenterInstitution":"Biothera","presenterCity":"Eagan","presenterCountry":"United States","keywords":"Checkpoint;Innate immunity;Innate immunity;Combination therapy","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"4717","name":"4717","title":"The highly specific CSF1R inhibitor DCC-3014 exhibits immunomodulatory and anti-invasive activities in cancer models","presenterFirst":"Bryan","presenterLast":"Smith","presenterInstitution":"Deciphera Pharmaceuticals","presenterCity":"Lawrence","presenterCountry":"United States","keywords":"c-Fms;Immunomodulation;Immunomodulation;Immunotherapy","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"4916","name":"4916","title":"Selinexor, a selective inhibitor of nuclear export (SINE) compound, shows synergistic anti-tumor activity when combined with PD-1 blockade in a mouse model of colon cancer","presenterFirst":"Sharon","presenterLast":"Friedlander","presenterInstitution":"Karyopharm Therapeutics Inc","presenterCity":"Newton","presenterCountry":"United States","keywords":"Nuclear-cytoplasmic transport;Combination studies;Combination studies;Immunotherapy","category":"CLINICAL RESEARCH","sage":"small combo CPI","moa":"other"},{"id":"5007","name":"5007","title":"Combination cancer immunotherapy using checkpoint blockade and intratumoral virus-like particles containing CpG ODN","presenterFirst":"Caitlin","presenterLast":"Lemke","presenterInstitution":"University of Iowa","presenterCity":"Iowa City","presenterCountry":"United States","keywords":"Melanoma/skin cancers;CpG oligodeoxynucleotides;CpG oligodeoxynucleotides;Checkpoint blockade","category":"CLINICAL RESEARCH","sage":"small combo CPI","moa":"immune"},{"id":"5066","name":"5066","title":"Role of the PD-1/PDL-1 pathway in resistance of patients with metastatic breast cancer to treatment with radiotherapy and TGF&#946; neutralization","presenterFirst":"Sandra","presenterLast":"Demaria","presenterInstitution":"Weill Cornell Medical College","presenterCity":"New York","presenterCountry":"United States","keywords":"Radiation therapy;Breast cancer;Breast cancer;Immunotherapy","category":"CLINICAL RESEARCH","sage":"small combo CPI","moa":"immune"},{"id":"5162","name":"5162","title":"Selinexor, a selective inhibitor of nuclear export (SINE), enhances the in vivo efficacy of checkpoint blockade with antibodies targeting CTLA4 or PD-1/PD-L1 in melanoma","presenterFirst":"Matthew","presenterLast":"Farren","presenterInstitution":"Ohio State University - James Comprehensive Cancer Center","presenterCity":"Columbus","presenterCountry":"United States","keywords":"Melanoma/skin cancers;Nuclear-cytoplasmic transport;Nuclear-cytoplasmic transport;Immunotherapy","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"other"},{"id":"5182","name":"5182","title":"Glutaminase inhibition with CB-839 enhances anti-tumor activity of PD-1 and PD-L1 antibodies by overcoming a metabolic checkpoint blocking T cell activation","presenterFirst":"Matt","presenterLast":"Gross","presenterInstitution":"Calithera Biosciences","presenterCity":"South San Francisco","presenterCountry":"United States","keywords":"Metabolism;Checkpoint;Checkpoint;Tumor microenvironment","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"other"},{"id":"5225","name":"5225","title":"Preclinical model of human melanoma for evaluation of targeted drug treatment and for immunotherapy validation","presenterFirst":"Rajaa","presenterLast":"El Meskini","presenterInstitution":"Leidos Biomedical Research, Inc.","presenterCity":"Frederick","presenterCountry":"United States","keywords":"Melanoma/skin cancers;Targeted therapy;Targeted therapy;Immunotherapy","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"oncogenic kinases"},{"id":"5255","name":"5255","title":"Intratumoral expression of IL-12 from a dendritic cell-targeting chimeric lentiviral vector from the ZVex platform cures established tumors in multiple models and induces systemic anti-tumor responses","presenterFirst":"Tina","presenterLast":"Albershardt","presenterInstitution":"Immune Design","presenterCity":"Seattle","presenterCountry":"United States","keywords":"Lentivirus;Tumor microenvironment;Tumor microenvironment;Interleukin-12","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"5265","name":"5265","title":"PT2385, a novel HIF-2&#945; antagonist, combines with checkpoint inhibitor antibodies to inhibit tumor growth in preclinical models by modulating myeloid cells and enhancing T cell infiltration","presenterFirst":"Tai","presenterLast":"Wong","presenterInstitution":"Peloton Therapeutics","presenterCity":"Dallas","presenterCountry":"United States","keywords":"Hypoxia-inducible factor;Renal cell carcinoma;Renal cell carcinoma;Checkpoint","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"oncogenic kinases"},{"id":"5296","name":"5296","title":"Small molecule T-reg inhibitors for cancer immunotherapy","presenterFirst":"Suresh","presenterLast":"Kumar","presenterInstitution":"Progenra, Inc.","presenterCity":"Malvern","presenterCountry":"United States","keywords":"Immunotherapy;T cell;T cell;Combination therapy","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"5313","name":"5313","title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","presenterFirst":"Weiyi","presenterLast":"Peng","presenterInstitution":"M.D. Anderson Cancer Center","presenterCity":"Houston","presenterCountry":"United States","keywords":"PTEN;NA;NA;NA","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"leucocyte kinases"},{"id":"5345","name":"5345","title":"Checkpoint blockade therapy is improved by altering the immune suppressive microenvironment with IPI-549, a potent and selective inhibitor of PI3K-gamma, in preclinical models","presenterFirst":"Olivier","presenterLast":"De Henau","presenterInstitution":"Memorial Sloan Kettering Cancer Center","presenterCity":"New York","presenterCountry":"United States","keywords":"Tumor immunity;Tumor associated macrophages;Tumor associated macrophages;PI3K","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"leucocyte kinases"},{"id":"5375","name":"5375","title":"HDAC6, new role as master regulator of PD-L1 and immune-related pathways","presenterFirst":"Alejandro","presenterLast":"Villagra","presenterInstitution":"The George Washington University","presenterCity":"Falls Church","presenterCountry":"United States","keywords":"Histone deacetylase;STAT3;STAT3;Melanoma/skin cancers","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"epigenetics"},{"id":"5439","name":"5439","title":"Epigenetic priming potentiates immune checkpoints inhibitors in ovarian cancer","presenterFirst":"Salvatore","presenterLast":"Condello","presenterInstitution":"Indiana University","presenterCity":"Indianapolis","presenterCountry":"United States","keywords":"Epigenetics;Ovarian cancer;Ovarian cancer;T cell","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"epigenetics"},{"id":"5614","name":"5614","title":"Anti-cancer efficacy of the combination with immunomodulatory antibodies and MEK inhibitor for Kras mutation and p53 knockout driven lung cancer","presenterFirst":"JaSeok Peter","presenterLast":"Koo","presenterInstitution":"Yale School of Medicine","presenterCity":"New Haven","presenterCountry":"United States","keywords":"Immunotherapy;K-ras;K-ras;Lung cancer: non-small cell","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"epigenetics"},{"id":"5627","name":"5627","title":"Chemo-induced biology of PD-L1 and <i>in vivo</i> combination immune therapy for ovarian cancer","presenterFirst":"Anda","presenterLast":"Vlad","presenterInstitution":"University of Pittsburgh, School of Medicine","presenterCity":"Pittsburgh","presenterCountry":"United States","keywords":"Ovarian cancer;Chemotherapy;Chemotherapy;Animal models","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"chemotherapy"},{"id":"5633","name":"5633","title":"BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy","presenterFirst":"James","presenterLast":"Lorens","presenterInstitution":"Department of Biomedicine, Center for Cancer Biomarkers, University of Bergen","presenterCity":"Bergen","presenterCountry":"Norway","keywords":"EMT;Tumor immunity;Tumor immunity;Mammary adenocarcinoma","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"oncogenic kinases"},{"id":"5792","name":"5792","title":"Immune competent syngeneic models demonstrate additive effects of combination strategies using checkpoint immunotherapy and inducers of immunogenic cell death (ICD)","presenterFirst":"Andrew","presenterLast":"Mckenzie","presenterInstitution":"Crown Bioscience UK Ltd","presenterCity":"Loughborough","presenterCountry":"United Kingdom","keywords":"Immunotherapy;NA;NA;NA","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"chemotherapy"},{"id":"5863","name":"5863","title":"The selective class I HDAC inhibitor entinostat enhances the antitumor effect of PD-1 inhibition in a syngeneic orthotopic murine model of renal cell carcinoma","presenterFirst":"Ashley","presenterLast":"Orillion","presenterInstitution":"Indiana University - Purdue University Indianapolis","presenterCity":"Indianapolis","presenterCountry":"United States","keywords":"Renal cell carcinoma;Anti-PD-1 immune checkpoint inhibitor;Anti-PD-1 immune checkpoint inhibitor;Histone deacetylase inhibitor","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"epigenetics"},{"id":"5935","name":"5935","title":"Combining Toca 511 and 5-fluorocytosine with &#945;PD-1 or &#945;CTLA-4 antibody significantly reduces tumor burden compared to either checkpoint inhibitor alone or in combination in a subcutaneous mouse glioma model","presenterFirst":"Leah","presenterLast":"Mitchell","presenterInstitution":"Tocagen","presenterCity":"San Diego","presenterCountry":"United States","keywords":"Retrovirus;Combination therapy;Combination therapy;Immunotherapy","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"5950","name":"5950","title":"Dinaciclib induces immunogenic cell death and enhances anti-PD-1 mediated tumor suppression","presenterFirst":"Dewan Mohammed Sakib","presenterLast":"Hossain","presenterInstitution":"Merck Research Laboratories","presenterCity":"Palo Alto","presenterCountry":"United States","keywords":"Cancer immunotherapy;CDK inhibitor;CDK inhibitor;Immunostimulation","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"oncogenic kinases"},{"id":"6041","name":"6041","title":"Preclinical combination strategies to enhance the efficacy of the anti-PD-1 antibody pembrolizumab","presenterFirst":"Elaine","presenterLast":"Pinheiro","presenterInstitution":"Merck & Co., Inc.","presenterCity":"Kenilworth","presenterCountry":"United States","keywords":"Combination therapy;PD-1;PD-1;NA","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"6161","name":"6161","title":"Hypomethylation therapy leads to immune polarization and improved efficacy of immunotherapy in transgenic model of pancreatic cancer","presenterFirst":"Tamas","presenterLast":"Gonda","presenterInstitution":"Columbia University","presenterCity":"NC","presenterCountry":"United States","keywords":"DNA methylation;Pancreatic cancer;Pancreatic cancer;NA","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"epigenetics"},{"id":"6403","name":"6403","title":"Durable antitumor activity of the CD122-biased immunostimulatory cytokine NKTR-214 combined with immune checkpoint blockade","presenterFirst":"John","presenterLast":"Langowski","presenterInstitution":"Nektar Therapeutics","presenterCity":"San Francisco","presenterCountry":"United States","keywords":"Cytokines;Preclinical;Preclinical;Checkpoint","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"6679","name":"6679","title":"Effects of chemotherapeutic agents on the tumor immune microenvironment","presenterFirst":"Marcia","presenterLast":"Belvin","presenterInstitution":"Genentech, Inc.","presenterCity":"South San Francisco","presenterCountry":"United States","keywords":"Chemotherapy;NA;NA;NA","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"chemotherapy"},{"id":"6696","name":"6696","title":"Effects of MAPK pathway inhibitors in the tumor immune microenvironment","presenterFirst":"Marcia","presenterLast":"Belvin","presenterInstitution":"Genentech, Inc.","presenterCity":"South San Francisco","presenterCountry":"United States","keywords":"Immune response;NA;NA;NA","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"oncogenic kinases"},{"id":"3101","name":"3101","title":"Taking the sweet out of Th17 cells to potentiate immuno-oncology drugs","presenterFirst":"Jason","presenterLast":"Chesney","presenterInstitution":"University of Louisville","presenterCity":"Louisville","presenterCountry":"United States","keywords":"T cell;Immunomodulation;Immunomodulation;Melanoma/skin cancers","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"},{"id":"7292","name":"7292","title":"Development of Axl/Mer inhibitor, ONO-9330547: preclinical evidence supporting the combination with immunotherapeutics","presenterFirst":"Kohei","presenterLast":"Tanaka","presenterInstitution":"Minase Research Institute/Ono Pharmaceutical Co., Ltd.","presenterCity":"Osaka","presenterCountry":"Japan","keywords":"Immunotherapy;Axl;Axl;Mertk","category":"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","sage":"small combo CPI","moa":"oncogenic kinases"},{"id":"7718","name":"7718","title":"Activatable nanodelivery combined with CpG-ODN and anti-PD-1 achieves a complete response in directly-treated and contralateral tumors in a murine breast cancer model","presenterFirst":"Katherine","presenterLast":"Ferrara","presenterInstitution":"University of California, Davis","presenterCity":"Davis","presenterCountry":"United States","keywords":"Immunomodulation;Drug delivery;Drug delivery;Doxorubicin","category":"CANCER CHEMISTRY","sage":"small combo CPI","moa":"chemotherapy"},{"id":"7763","name":"7763","title":"Combination therapy of immune checkpoint and nuclear exporter inhibitors in a renal cell carcinoma mouse model","presenterFirst":"Robert","presenterLast":"Weiss","presenterInstitution":"UC Davis","presenterCity":"Davis","presenterCountry":"United States","keywords":"Checkpoint;NA;NA;NA","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"other"},{"id":"7816","name":"7816","title":"Phase II trial of theiIndoleamine 2, 3-dioxygenase pathway (IDO) inhibitor indoximod plus immune checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma","presenterFirst":"Yousef","presenterLast":"Zakharia","presenterInstitution":"University of Iowa, Holden Comprehensive Cancer Center","presenterCity":"IOWA CITY","presenterCountry":"United States","keywords":"Melanoma/skin cancers;IDO Inhibitor;IDO Inhibitor;Checkpoint","category":"CLINICAL TRIALS","sage":"small combo CPI","moa":"immune"},{"id":"7821","name":"7821","title":"Imprime PGG drives adaptive immune resistance within the tumor microenvironment by modulating the myeloid compartment and enhances the efficacy of anti-PD1 antibody in vivo","presenterFirst":"Adria","presenterLast":"Bykowski Jonas","presenterInstitution":"Biothera","presenterCity":"Eagan","presenterCountry":"United States","keywords":"Checkpoint;Innate immunity;Innate immunity;NA","category":"IMMUNOLOGY","sage":"small combo CPI","moa":"immune"}]},{"id":"small combo other","name":"small combo other","presenterLast":"small combo other","children":[{"id":"2050","name":"2050","title":"KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110&#946;/p110&#948; and HDAC6 with single-agent and combination activity","presenterFirst":"Stephen","presenterLast":"Shuttleworth","presenterInstitution":"Karus Therapeutics Ltd","presenterCity":"Abingdon, Oxfordshire","presenterCountry":"United Kingdom","keywords":"Immunotherapy;PI3K;PI3K;Histone deacetylase","category":"IMMUNOLOGY","sage":"small combo other","moa":"leucocyte kinases"},{"id":"3213","name":"3213","title":"The oncolytic peptide LTX-315 enhances tumor-specific immune responses and tumor regression in murine 4T1 breast cancer when combined with doxorubicin","presenterFirst":"\u00d8ystein","presenterLast":"Rekdal","presenterInstitution":"Lytix Biopharma","presenterCity":"Oslo","presenterCountry":"Norway","keywords":"Peptides;Oncolytic;Oncolytic;Immunotherapy","category":"IMMUNOLOGY","sage":"small combo other","moa":"immune"},{"id":"5665","name":"5665","title":"GPC3-specific chimeric antigen receptor T cell in combination with Sorafenib as a novel therapeutic treatment for hepatocellular carcinoma","presenterFirst":"Thu Le","presenterLast":"Trinh","presenterInstitution":"Moffitt Cancer Center","presenterCity":"Tampa","presenterCountry":"United States","keywords":"Sorafenib;Glypican-3;Glypican-3;Adoptive immunotherapy","category":"IMMUNOLOGY","sage":"small combo other","moa":"oncogenic kinases"}]}]}
